Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways.

Acta Pharmacologica Sinica
Miao YuYing-Li Wu

Abstract

The kinase FLT3 internal tandem duplication (FLT3-ITD) is related to poor clinical outcomes of acute myeloid leukemia (AML). FLT3 inhibitors have provided novel strategies for the treatment of FLT3-ITD-positive AML. But they are limited by rapid development of acquired resistance and refractory in monotherapy. Recent evidence shows that inducing the degradation of FLT3-mutated protein is an attractive strategy for the treatment of FLT3-ITD-positive AML, especially those with FLT3 inhibitor resistance. In this study we identified Wu-5 as a novel USP10 inhibitor inducing the degradation of FLT3-mutated protein. We showed that Wu-5 selectively inhibited the viability of FLT3 inhibitor-sensitive (MV4-11, Molm13) and -resistant (MV4-11R) FLT3-ITD-positive AML cells with IC50 of 3.794, 5.056, and 8.386 μM, respectively. Wu-5 (1-10 μM) dose-dependently induced apoptosis of MV4-11, Molm13, and MV4-11R cells through the proteasome-mediated degradation of FLT3-ITD. We further demonstrated that Wu-5 directly interacted with and inactivated USP10, the deubiquitinase for FLT3-ITD in vitro (IC50 value = 8.3 µM) and in FLT3-ITD-positive AML cells. Overexpression of USP10 abrogated Wu-5-induced FLT3-ITD degradation and cell death. Also, the co...Continue Reading

References

Jun 25, 2014·Mediterranean Journal of Hematology and Infectious Diseases·Ghaleb ElyamanyAbdulaziz Al-Abulaaly
Sep 11, 2014·Molecular Cancer Therapeutics·Mary Ellen MolloyDebra A Tonetti
Nov 14, 2015·Annual Review of Pharmacology and Toxicology·Daniel Martinez Molina, Pär Nordlund
Dec 10, 2015·Cellular and Molecular Neurobiology·Nailya S Gliyazova, Gordon C Ibeanu
Feb 16, 2016·Molecular Cell·Min DengZhenkun Lou
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Jun 12, 2016·Blood·Klaus H MetzelerUNKNOWN AMLCG Study Group
May 5, 2017·Medical Oncology·Francisco Alejandro Lagunas-Rangel, Venice Chávez-Valencia
Oct 3, 2017·Nature Chemical Biology·Ellen L WeisbergSara J Buhrlage
Jun 19, 2018·Cell Stem Cell·Shanshan PeiCraig T Jordan
Nov 15, 2018·Journal of the American Chemical Society·George M BurslemCraig M Crews
Apr 13, 2019·Journal of Experimental & Clinical Cancer Research : CR·Yuning LiaoHongbiao Huang
Jul 7, 2019·Critical Reviews in Oncology/hematology·Taylor M WeisAnthony J Perissinotti
Sep 8, 2019·European Journal of Pharmacology·Akira Shimada
Dec 7, 2019·Hematology·Catherine C Smith

❮ Previous
Next ❯

Citations

Aug 30, 2021·Biomarker Research·Hu LeiYingli Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.